VinBrain, a pioneering AI HealthTech company within Vingroup conglomerate, has officially signed a commercial agreement with Global Fund to transfer Artificial Intelligence (AI) technology for Tuberculosis (TB) screening and detection as part of Vietnam’s National Tuberculosis Prevention Campaign.
Read also – AirAsia MOVE and HTS Announce New Partnership
VinBrain is the sole entity chosen for this agreement with Global Fund in 2024. DrAid™ for TB Screening, a solution developed from VinBrain’s innovative and visionary approach to applying advanced technology, aligns with the stringent criteria of the Fund, contributing to community health and progress.
Read also – ICG invests in Singapore-based Alfa Medicus
The collaboration aims to transform TB detection using advanced AI technology, significantly reducing diagnosis time by analyzing X-ray images. This eliminates the need for extra TB bacterial PCR tests, cutting screening costs from US$50-60 to only US$1. Furthermore, the AI outputs its results in a file or QR code format, reducing environmental impact. Under this agreement, VinBrain plans to transfer the technology of 32 AI licenses, enables the screening of 1 million suspected TB cases starting in April 2024. This marks the largest scale initiative of its kind to date.
About VinBrain
Founded in 2019 VinBrain, a leading Vietnam-based HealthTech innovator, funded by Vingroup, the largest conglomerate by market capitalization in Vietnam. It is revolutionizing healthcare with the power of AI. It’s products leverage the boundless potential of Artificial Intelligence (AI), Computer Vision, and Machine Learning to create tailored solutions for the healthcare sector.
